Stryker Corporation (“Stryker”) recently announced that it has entered into a definitive agreement to acquire Inari Medical, Inc. (“Inari”) for approximately $4.9 billion.
Inari develops technologies and products for treating pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula. Inari’s products include the FlowTriever® Retrieval/Aspiration System, the ClotTriever® Thrombectomy System, the RevCore™ Thrombectomy Catheter, and the InThrill™ Thrombectomy System. Analysts report that venous thromboembolism is a big market affecting 900,000 people in the United States each year.
Stryker is a global leader in medical technologies, offering medical and surgical equipment and products and services for Neurotechnology and Orthopaedics in about 75 countries which impact more than 150 million patients annually.
Regarding the acquisition, Kevin Lobo, the Chair and Executive Officer of Stryker, stated:
The acquisition of Inari expands Stryker’s portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases. These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker’s impact in endovascular procedures.
Drew Hykes, the Chief Executive Officer of Inari, stated:
Inari has positively impacted the lives of hundreds of thousands of patients through the development of purpose-built tools that address unmet patient needs. With Stryker’s capabilities and global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint.
A press release regarding the acquisition is available here.
